Effective Immunochemotherapy For Aggressive Non-Hodgkin’s Lymphoma
- 29 February 2004
- journal article
- Published by Elsevier in Seminars in Oncology
- Vol. 31, 7-11
- https://doi.org/10.1053/j.seminoncol.2003.12.003
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphomaBlood, 2003
- Rituximab as First-Line and Maintenance Therapy for Patients With Indolent Non-Hodgkin’s LymphomaJournal of Clinical Oncology, 2002
- Shortened First-Line High-Dose Chemotherapy for Patients With Poor-Prognosis Aggressive LymphomaJournal of Clinical Oncology, 2002
- CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaNew England Journal of Medicine, 2002
- Survival Benefit of High-Dose Therapy in Poor-Risk Aggressive Non-Hodgkin’s Lymphoma: Final Analysis of the Prospective LNH87–2 Protocol—A Groupe d’Etude des Lymphomes de l’Adulte StudyJournal of Clinical Oncology, 2000
- Randomized Comparison of ACVBP and m-BACOD in the Treatment of Patients With Low-Risk Aggressive Lymphoma: The LNH87-1 StudyJournal of Clinical Oncology, 2000
- A randomised comparison of a third-generation regimen (PACEBOM) with a standard regimen (CHOP) in patients with histologically aggressive non-Hodgkin's lymphoma: a British National Lymphoma Investigation reportBritish Journal of Cancer, 1996
- Bcl-2 family proteins: regulators of chemoresistance in cancerToxicology Letters, 1995
- Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993
- ADVANCED DIFFUSE HISTIOCYTIC LYMPHOMA, A POTENTIALLY CURABLE DISEASEThe Lancet, 1975